Vanda Pharmaceuticals (VNDA) Shares are Down -1.01%

Vanda Pharmaceuticals (VNDA) has risen sharply, recording gains of 7.01% in the past 4 weeks. However, the stock has corrected -1.01% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 7.59% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 3.86% and the 50-Day Moving Average is 19.35%.The 200 Day SMA reached 60.12%


Vanda Pharmaceuticals (NASDAQ:VNDA): After opening at $16.4, the stock dipped to an intraday low of $16.2 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $17.26 and the buying power remained strong till the end. The stock closed at $16.64 for the day, a gain of 2.34% for the day session. The total traded volume was 1,235,286. The stocks close on the previous trading day was $16.64.

Vanda Pharmaceuticals (VNDA) : Currently there are 4 street experts covering Vanda Pharmaceuticals (VNDA) stock. The most bullish and bearish price target for the stock is $24 and $15 respectively for the short term. The average price target of all the analysts comes to $20. The estimated standard deviation from the target is $3.92.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Companys product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. HETLIOZ (tasimelteon) is a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) for which a New Drug Application (NDA) was approved by the United States Food and Drug Administration (FDA). Fanapt (iloperidone) is a product for the treatment of schizophrenia. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is under clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *